Cuprina to Acquire Seven-Clinic Singapore Healthcare Group for S$4M
CUPR sits 81% above its 52-week low of $1.445.
Summary
Cuprina is buying East Coast Podiatry (five clinics) and Orchard Clinic (two clinics) for about S$4.0 million (US$3.1 million), with 75% cash and 25% stock subject to lock-up. The consideration comprises S$0.5 million cash on signing, S$1.35 million cash at completion, S$1.0 million in consideration shares, and S$1.15 million deferred cash. The target group generated S$9.1 million revenue and S$1.2 million normalized EBITDA in FY2025, implying a purchase price of roughly 3.3x EBITDA. This is a transformative deal for a company with a market cap of only $13.4 million, adding a profitable clinical platform directly aligned with its wound-care and collagen technologies. The acquisition follows a highly dilutive offering in September that raised $4.97 million at $1.15 per share, and the company is also seeking a 100x increase in authorized shares. Completion is expected by November 1, 2026, after which Cuprina will consolidate the target's financials.
Updated with an SEC 6-K filing · What changed
Updates
· SEC 6-K — The 6-K details the S$4.0M consideration: S$0.5M cash on signing, S$1.35M cash at completion, S$1.0M in consideration shares, and S$1.15M deferred cash.
At the time of this announcement, CUPR was trading at $2.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.4M. The 52-week trading range was $1.45 to $14.80. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.